Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • How big is the problem?
    • How we drive change
    • Our story
  • Featured insights
    • The latest at the Foundation
    • The latest at the Foundation
  • Sectors and research
    • Big pharma
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company report cards & comparison
    • Big pharma
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company report cards & comparison
  • Become a catalyst
    • For investors
    • For companies
    • For government and policy makers
    • Events & engagements
    • For investors
    • For companies
    • For government and policy makers
    • Events & engagements
  • Achievements so far
    • The Foundation's impact
    • The Foundation's impact
  • News
  • Our team
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Access plans increasingly part of drugmakers’ strategies, says report

The Hindu businessline reports on the launch of the 2022 Access to Medicine Index, highlighting the Index's findings on the overall improvement in pharma companies’ access efforts.

Date

15 November 2022

Direct links

Read the article

While companies have increasingly included access plans in their efforts to expand access to their products in low- and middle-income countries (LMICs), there is room for improvement.

Speaking to The Hindu, James Hazel, Research Programme Manager for the 2022 Access to Medicine Index, tells journalist Jyothi Datta: “Companies must consider the depths of their plans, strength of their supply chains, and equity of their pricing strategies to reach the most vulnerable populations.”

In analysing the 2022 Index ranking, the publication also highlights one of the Key Findings of the latest Index, which is that the pipeline for R&D projects covering emerging infectious diseases (excluding COVID-19 and other coronaviral diseases) has remained mainly empty.

Read the article on The Hindu businessline website.

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Copyright 2004 - 2022 Access to Medicine Foundation - All Rights Reserved